InvestorsHub Logo
Followers 0
Posts 107
Boards Moderated 0
Alias Born 03/07/2017

Re: None

Thursday, 08/10/2017 12:44:17 PM

Thursday, August 10, 2017 12:44:17 PM

Post# of 1400
$HADV Health Advance Inc. ~ In other industry news, other financial results and market performance of note:

Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) closed up 21.21% on Wednesday at $7.60 with over 4.2 million shares traded by the market close and was further up slightly in afterhours trading. The company recently announced top-line results from its double-blind placebo controlled Phase 2 STAR 1 (Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy) clinical trial evaluating ZYN002 (cannabidiol [CBD] gel) in adult epilepsy patients with focal seizures.

GW Pharmaceuticals plc (NASDAQ: GWPH) recently announced financial results for the third quarter ended 30 June 2017. "I am pleased to report the NDA submission process for Epidiolex is now underway with the final sections of the submission expected to be completed in October. With a clear view now towards our anticipated approval, we are making excellent progress with preparations to ensure a highly successful launch in 2018," stated Justin Gover, GW's Chief Executive Officer. "Following the recent publication of our first Phase 3 trial in The New England Journal of Medicine, we look forward to additional Epidiolex data publications and presentations in the second half of the year.

Source: https://finance.yahoo.com/news/gw-pharmaceuticals-plc-reports-fiscal-200500100.html